Cat. #162059
Anti-deltaNp63 [PANp63-6.1]
Cat. #: 162059
Sub-type: Primary antibody
Target: tumour protein p63 lacking the transactivation domain (TA)
Class: Monoclonal
Reactivity: Human ; mouse ; rat
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Institute: Moravian Biotechnology
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-deltaNp63 [PANp63-6.1]
- Clone: PANp63-6.1
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Molecular weight: 72-76 kDa (variable, depending on the p63 isoform present)
- Reactivity: Human ; mouse ; rat
- Host: Mouse
- Description: Antibody created to detect the deltaN isoform of p63 (deltaNp63) with tumour suppressor role and differentiate from the TA (TAp63) isoforms of the same protein. Binding specificity: Epitope mapping using phage display identified the epitope PSHLIR, which occurs twice within the central region of p63. The antibody recognizes TAp63 and deltaNp63. The antibody does not cross-react with p53 or any p73 isoform tested.
- Immunogen: PSHLIR sequence of tumour protein p63 (deltaN isoform)
- Isotype: IgG1 kappa
- Production details: B cell donor: Splenocytes from mouse immunised with recombinant TAp63?, Fusion partner: SP2
Target Details
- Target: tumour protein p63 lacking the transactivation domain (TA)
- Molecular weight: 72-76 kDa (variable, depending on the p63 isoform present)
- Target background: p63 is a transcription factor of the p53 gene family, encoded by the TP63 gene located at chromosome 3q28. p63 exists as N-terminal isoforms that either contain (TAp63) or lack (deltaNp63) the p53-like transactivation domain at the N-terminus. C-terminal isoforms are produced by alternative splicing of 3' exons. TAp63 is involved in germ cell maintenance and myocyte differentiation, and is expressed in some lymphocytes and lymphomas/leukemias.
- Epitope sequence: PSHLIR
Handling
- Format: Liquid
References
- Nekulova et al. 2013. Virchows Arch. Sep:463(3):415-25. PMID: 23887585
- Liu et al. 2020. J Pathol Clin Res. Jan:6(1):83-93. PMID: 31591823
- Galoczova et al. 2021. Virchows Arch. Apr:478(4):627-636. PMID: 33037932
- Stenckova et al. 2023. Neoplasma Oct:70(5):621-632. PMID: 38053383
